IMR Press / FBL / Volume 23 / Issue 8 / DOI: 10.2741/4653

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Modified lipoproteins as biomarkers of atherosclerosis

Show Less
1 Institute for Atherosclerosis Research, Skolkovo Innovative Center, Russian Federation, 143025 Moscow, Russia
2 Institute of General Pathology and Pathophysiology, Russian Federation, 125315 Moscow, Russia
3 Russian Cardiology Research and Production Complex, Moscow, Russian Federation, 125315 Moscow, Russia
Front. Biosci. (Landmark Ed) 2018, 23(8), 1422–1444;
Published: 1 March 2018

Pathogenesis of atherosclerosis and the search for novel therapies and diagnostic markers remain major problems of modern medicine. Currently available therapeutic approaches are often not sufficiently effective, probably due to the complexity of the disease mechanisms. This review focuses on the evaluation of low density lipoprotein (LDL) and high density lipoprotein (HDL) as risk factors of atherosclerosis. We summarize the current paradigm of LDL involvement in atherogenesis and HDL presumably protective properties. We next discuss the available evidence for the protective effect of HDL and the consequences of HDL dysfunction. Finally, we question the currently widely accepted hypothesis of the central role of oxidized LDL in atherogenesis and present an alternative concept of multiple modification of LDL that confers its pro-atherogenic properties.

cardiovascular disease
modified LDL
Back to top